EQL EQL Pharma AB (publ)

2.234USD22.70 SEK · STO+2.02%Mkt Cap: 65.98M USDP/E: 756.67

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including h…

Key Statistics

Company
Market Cap65.98M USD
Enterprise Value105.36M USD
Revenue (TTM)49.53M USD
Gross Profit16.03M USD
Net Income (TTM)1.23M USD
Revenue/Share1.68 USD
Last Price2.234 USD
Fiscal Year EndMar 2026
MR QuarterSep 2026
Employees65
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0005497732
Valuation
P/E (Trailing)756.67
P/E (Forward)7.25
PEG—
EV/EBITDA19.68
EV/Revenue2.13
P/S1.33
P/B2.56
EPS (TTM)0.0030 USD
EPS (Forward)0.31 USD
52W Range
1.71111% of range6.644
52W High6.644 USD
52W Low1.711 USD
Profitability
Gross Margin37.64%
Oper. Margin6.47%
EBITDA Margin10.81%
Profit Margin2.90%
ROE4.69%
ROA1.47%
ROIC5.10%
ROCE7.40%
Growth
Revenue Growth82.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF2.79M USD
CapEx (TTM)6.62M USD
FCF Margin-5.92%
FCF Yield-4.45%
Net Debt39.38M USD
Net Debt/EBITDA7.36
Net Debt/FCF—
Balance Sheet
Debt/Equity1.72
Current Ratio2.01
Quick Ratio1.06
Book Value/Sh0.87 USD
Cash/Share0.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.429 USD
Upside (mean)+98.2%
Target Range4.429 USD – 4.429 USD
# Analysts1
Ownership
Shares Out.29.53M
Float12.80M
Insiders57.70%
Institutions18.32%
Technical
SMA 502.266 (-1.4%)
SMA 2003.287 (-32.0%)
Beta0.35
S&P 52W Chg12.00%
Avg Vol (30d)28.52K
Avg Vol (10d)33.26K
Technical Indicators
RSI (14)46.8
MACD0.4640
MACD Signal0.5183
MACD Hist.-0.0544
BB Upper2.772 USD
BB Middle2.242 USD
BB Lower1.711 USD
BB Width47.33%
ATR (14)0.1636 USD
Vol Ratio (20d)1.05x

About EQL Pharma (STO: EQL)

›

EQL Pharma (STO: EQL) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 65 employees.

The shares were at 22.70 SEK on 19 November 2026, down 56.5% over 52 weeks. Its 52-week range is 17.38 SEK to 67.50 SEK: the price is 66.4% below the high and 30.6% above the low.

Its market capitalisation is 670.32M SEK.

EQL Pharma reports return on equity of 4.7%, an operating margin of 6.5% and revenue up 82.0% year over year.

Its debt exceeds its cash by 400.13M SEK, a debt-to-equity ratio of 1.72. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 45.00 SEK is 98.2% above the current price.